PPIG and metabolic dysfunction-associated steatotic liver disease: Finally, we showed that MPCCs augmented with activated (myofibroblastic) HSCs displayed the early stages of nonalcoholic fatty liver disease (NAFLD) with steatosis in PHHs, downregulation of CYP enzymes and transporters, and collagen-I deposition by HSCs; this model system was shown to be amenable to screening of clinically relevant compounds and their combinations on alleviating the hepatic dysfunctions in NAFLD.36